COVID-KOSHA
Home
Help
(current)
!
Note: Language translations may be imperfect
A model anti-pandemic portal for scientists & public
Antiviral efficacy
Last updated: 2022 Jul 13
Total hit(s): 116
---Sort by---
Key findings ▲
Key findings ▼
Date of publishing ▲
Date of publishing ▼
Citation Count ▲
Citation Count ▼
Impact Factor ▲
Impact Factor ▼
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
12.5µg of Oridonin had zero relative copies of viral
RNA
in the supernatant of VeroE6 cells, 48hrs post-infection. Oridonin had an inhibitory EC
50
of 4.95µm. Catalytic activity of 3CLpro in vitro was inhibited by Oridonin at an IC
50
of 2.16µm.
Oridonin is a novel candidate to develop a new antiviral treatment for COVID-19.
✍
35600064
(
)
PMID
35600064
Title
Oridonin Inhibits SARS-CoV-2 by Targeting Its 3C-Like Protease
Impact factor
N/A
Date of Entry
2022 Jul 13
×
NLM format
Oridonin Inhibits SARS-CoV-2 by Targeting Its 3C-Like Protease. . . PMID:35600064
Eleven naturally occuring polyether ionophores and one synthetic analog were screened and found that all of them display inhibitory activity but X-206 showed high selectivity of 584-fold, and could inhibit viral replication at EC
50
= 14 nM.
Some polythereionophores accumulate in lysosomes and inhibits autophagy and alters pH because of exchange of metal cations for protons which may underlie antiviral activity.
✍
33248195
(
Antiviral Res
)
PMID
33248195
Date of Publishing
: 2021 Jan
Title
Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro
Author(s) name
Svenningsen EB, Thyrsted J et al.
Journal
Antiviral Res
Impact factor
4.12
Citation count
: 2
Date of Entry
2022 Jan 17
×
NLM format
Svenningsen EB, Thyrsted J, Blay-Cadanet J, Liu H, Lin S, Moyano-Villameriel J, Olagnier D, Idorn M, Paludan SR, Holm CK, Poulsen TB. Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro. Antiviral Res. 2021 Jan;185:104988. PMID:33248195
VeroE6 cells infected with SARS-CoV-2 WT (B.1.1.70) or VOC
B.1.1.7
(alpha)
and
B.1.351
(beta)
strains, on treatment with budesonide or Pulmicort showed reduced viral titers at IC50 ranging between 4.8 and 20 µ
;M.
Cytotoxicity assay revealed no effect on the cell viability.
✍
34372616
(
Viruses
)
PMID
34372616
Date of Publishing
: 2021 Jul 20
Title
Antiviral Effect of Budesonide against SARS-CoV-2
Author(s) name
Heinen N, Meister TL et al.
Journal
Viruses
Impact factor
3.76
Citation count
: 4
Date of Entry
2021 Nov 23
×
NLM format
Heinen N, Meister TL, Klöhn M, Steinmann E, Todt D, Pfaender S. Antiviral Effect of Budesonide against SARS-CoV-2. Viruses. 2021 Jul 20;13(7):1411. PMID:34372616
SID 26681509 significantly inhibits SARS-CoV-2 pseudovirus infection in Huh7 cells.
SID 26681509 exhibits cytotoxicity, hence not used for further experiments.
✍
33774649
(
Signal Transduct Target Ther
)
PMID
33774649
Date of Publishing
: 2021 Mar 27
Title
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Author(s) name
Zhao MM, Yang WL et al.
Journal
Signal Transduct Target Ther
Impact factor
- n/a -
Citation count
: 73
Date of Entry
2021 Aug 23
×
NLM format
Zhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, Hou W, Fan CF, Jin RH, Feng YM, Wang YC, Yang JK. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021 Mar 27;6(1):134. PMID:33774649
Amantadine inhibits SARS-CoV-2 pseudovirus infection in Huh7 cells by reducing the Cathepsin L
(CTSL)
enzyme activity.
Amantadine can be used as a therapeutic.
✍
33774649
(
Signal Transduct Target Ther
)
PMID
33774649
Date of Publishing
: 2021 Mar 27
Title
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Author(s) name
Zhao MM, Yang WL et al.
Journal
Signal Transduct Target Ther
Impact factor
- n/a -
Citation count
: 73
Date of Entry
2021 Aug 23
×
NLM format
Zhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, Hou W, Fan CF, Jin RH, Feng YM, Wang YC, Yang JK. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021 Mar 27;6(1):134. PMID:33774649
E64d inhibits SARS-CoV-2 pseudovirus infection in Huh7 cells by reducing the Cathepsin L
(CTSL)
enzyme activity.
E64d can be used as a therapeutic as it inhibits CTSL enzyme activity.
✍
33774649
(
Signal Transduct Target Ther
)
PMID
33774649
Date of Publishing
: 2021 Mar 27
Title
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Author(s) name
Zhao MM, Yang WL et al.
Journal
Signal Transduct Target Ther
Impact factor
- n/a -
Citation count
: 73
Date of Entry
2021 Aug 23
×
NLM format
Zhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, Hou W, Fan CF, Jin RH, Feng YM, Wang YC, Yang JK. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021 Mar 27;6(1):134. PMID:33774649
Antiviral efficacy of Astemizole which inhibits the entry of SARS-CoV-2 Spike pseudoviruses into
ACE2-
expressed HEK293T cells by
binding
to the
ACE2
receptor.
SARS-COV-2 Spike pseudotype virus to enter the ACE2 cells were reduced significantly.
✍
33932547
(
Microb Pathog
)
PMID
33932547
Date of Publishing
: 2021 Apr 28
Title
Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro
Author(s) name
Wang X, Lu J et al.
Journal
Microb Pathog
Impact factor
2.64
Citation count
: 2
Date of Entry
2021 Aug 10
×
NLM format
Wang X, Lu J, Ge S, Hou Y, Hu T, Lv Y, Wang C, He H. Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro. Microb Pathog. 2021 Jul;156:104929. PMID:33932547
Type I PRMT
inhibitor
(MS023) inhibits interaction of
N
protein with the 5-UTR of SARS-CoV-2 genomic
RNA,
a property required for viral packaging.
PRMT inhibitors, cancer drug canditates, have found to methylate arginine in the N protein, thereby regulating the SARS-CoV-2 lifecycle.
✍
34029587
(
J Biol Chem
)
PMID
34029587
Date of Publishing
: 2021 May 23
Title
Arginine methylation of SARS-Cov-2 nucleocapsid protein regulates RNA binding, its ability to suppress stress granule formation, and viral replication
Author(s) name
Cai T, Yu Z et al.
Journal
J Biol Chem
Impact factor
3.96
Citation count
: 11
Date of Entry
2021 Jul 28
×
NLM format
Cai T, Yu Z, Wang Z, Liang C, Richard S. Arginine methylation of SARS-Cov-2 nucleocapsid protein regulates RNA binding, its ability to suppress stress granule formation, and viral replication. J Biol Chem. 2021 May 23;297(1):100821. PMID:34029587
Anti-viral activity of six drugs (arbidol, baloxavir, laninamivir, oseltamivir, peramivir, and zanamivir) against SARS-Co-V-2 was tested and among them only arbidol compound demonstrated to efficiently inhibit the virus infection in vitro.
Further clinical studies on Arbidol should be done to check its efficacy and validate the recommended dosage to treat COVID-19 patients.
✍
32373347
(
Cell Discov
)
PMID
32373347
Date of Publishing
: 2020
Title
The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
Author(s) name
Wang X, Cao R et al.
Journal
Cell Discov
Impact factor
4.65
Citation count
: 122
Date of Entry
2021 Jun 15
×
NLM format
Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, Yang X, Shi Z, Deng F, Hu Z, Zhong W, Wang M. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020 May 2;6:28. PMID:32373347
In vitro activity of three Abl tyrosine kinase inhibitors- nilotinib, imatinib and dasatinib against SARS-CoV-2 was analysed in Vero-E6 and Calu-3 cells.
The combinational therapy using antiviral and anti-inflammatory drugs is found to be one of the effective strategy to combat SARS-CoV-2.
✍
33232578
(
Basic Clin Pharmacol Toxicol
)
PMID
33232578
Date of Publishing
: 2020 Nov 24
Title
The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro
Author(s) name
Cagno V, Magliocco G et al.
Journal
Basic Clin Pharmacol Toxicol
Impact factor
2.29
Citation count
: 14
×
NLM format
Cagno V, Magliocco G, Tapparel C, Daali Y. The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro. Basic Clin Pharmacol Toxicol. 2021 Apr;128(4):621-624. PMID:33232578
Invitro studies of chlorpheniramine shows strong virucidal effect against SARS-CoV-2 infected Vero cell line.
CPM's antivirial and anti-inflammatory effects , with minimal side effects could be used in the early treatment and prevention of viral infections like influenzaA/B and COVID-19.
✍
32963923
(
Cureus
)
PMID
32963923
Date of Publishing
: 2020 Sep 17
Title
In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2
Author(s) name
Westover JB, Ferrer G et al.
Journal
Cureus
Impact factor
- n/a -
Citation count
: 9
×
NLM format
Westover JB, Ferrer G, Vazquez H, Bethencourt-Mirabal A, Go CC. In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2. Cureus. 2020 Sep 17;12(9):e10501. PMID:32963923
Ciclesonide showed increased IC50 (by >2 fold change) in Calu-3 cells compared to Vero cells.
Ciclesonide showed IC50 of 4.33 micromolar in Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Berbamine hydrochloride showed increased IC50 (by >4 fold change) in Calu-3 cells compared to Vero cells.
Berbamine hydrochloride IC50 of 7.87 micromolar in Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Amodiaquine dihydrochloride showed increased IC50 (by >4 fold change) in Calu-3 cells compared to Vero cells.
Amodiaquine dihydrochloride IC50 of 5.15 micromolar in Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Salinomycin sodium showed increased IC50 (by >2 fold change) in Calu-3 cells compared to Vero cells.
Salinomycin sodium IC50 of 0.24 micromolar in Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Mefloquine showed increased IC50 (by >4 fold change) in Calu-3 cells compared to Vero cells.
Mefloquine showed IC50 of 4.33 micromolar in Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Lopinavir
showed increased IC50 (by >2 fold change) in Calu-3 cells compared to Vero cells.
Lopinavir showed IC50 of 9.12 micromolar in Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Digitoxin showed decreased IC50 (by <1 fold change) in Calu-3 cells compared to Vero cells.
Digitoxin showed IC50 of 0.23 micromolar de Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Cyclosporine showed decreased IC50 (by <1 fold change) in Calu-3 cells compared to Vero cells.
Cyclosporine showed IC50 of 5.82 micromolar de Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Ouabain showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells.
Ouabain showed IC50 of 0.1 micromolar un Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Eltrombopag showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells.
Eltrombopag showed IC50 of 8.27 micromolar un Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Loperamide hydrochloride showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells.
Loperamide hydrochloride IC50 of 9.27 micromolar un Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Hexachlorophene showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells.
Hexachlorophene showed IC50 of 0.9 micromolar un Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Ivacaftor showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells.
Ivacaftor showed IC50 of 6.57 micromolar un Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684
Oxyclozanide showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells.
Oxyclozanide showed IC50 of 3.71 micromolar un Vero cells
✍
32767684
(
J Med Virol
)
PMID
32767684
Date of Publishing
: 2020 Aug 7
Title
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) name
Ko M, Jeon S et al.
Journal
J Med Virol
Impact factor
2.07
Citation count
: 40
×
NLM format
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021 Mar;93(3):1403-1408. PMID:32767684